
Konrad Gabrusiewicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1368882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology, 2020, 38, 947-953.	17.5	692
2	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	1.2	463
3	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 2016, 1, .	5.0	356
4	Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncolmmunology, 2018, 7, e1412909.	4.6	247
5	Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. Journal of Clinical Investigation, 2018, 129, 137-149.	8.2	242
6	Characteristics of the Alternative Phenotype of Microglia/Macrophages and its Modulation in Experimental Gliomas. PLoS ONE, 2011, 6, e23902.	2.5	239
7	The Controversial Role of Microglia in Malignant Gliomas. Clinical and Developmental Immunology, 2013, 2013, 1-12.	3.3	166
8	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 2016, 18, 639-648.	1.2	161
9	Distinct roles of <scp>CSF</scp> family cytokines in macrophage infiltration and activation in glioma progression and injury response. Journal of Pathology, 2013, 230, 310-321.	4.5	137
10	The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain, 2007, 130, 476-489.	7.6	124
11	Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine A-induced cell death. Oncogene, 2013, 32, 1518-1529.	5.9	123
12	Targeting the $\hat{l}\pm v$ integrin/TGF- \hat{l}^2 axis improves natural killer cell function against glioblastoma stem cells. Journal of Clinical Investigation, 2021, 131, .	8.2	117
13	Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	112
14	Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget, 2014, 5, 2208-2220.	1.8	108
15	Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Research, 2007, 1137, 161-169.	2.2	90
16	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. Journal of the National Cancer Institute, 2015, 107, .	6.3	80
17	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nature Communications, 2019, 10, 448.	12.8	65
18	Down-regulation of IKKÎ ² expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget, 2015, 6, 33077-33090.	1.8	55

Konrad Gabrusiewicz

#	Article	IF	CITATIONS
19	Silencing of cellular prion protein (PrPC) expression by DNA-antisense oligonucleotides induces autophagy-dependent cell death in glioma cells. Autophagy, 2011, 7, 840-853.	9.1	48
20	The Antitumorigenic Response of Neural Precursors Depends on Subventricular Proliferation and Age. Stem Cells, 2008, 26, 2945-2954.	3.2	47
21	Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget, 2016, 7, 72021-72032.	1.8	44
22	TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Science Advances, 2016, 2, e1501290.	10.3	33
23	Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget, 2016, 7, 16146-16157.	1.8	29
24	Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia, 2015, 17, 374-384.	5.3	28
25	Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Letters, 2018, 433, 176-185.	7.2	28
26	Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro-Oncology, 2016, 19, now198.	1.2	23
27	Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncolmmunology, 2016, 5, e1117739.	4.6	7
28	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. Journal of Neuro-Oncology, 2018, 136, 33-39.	2.9	4
29	Abstract B65: CT-0508, a novel CAR macrophage product directed against HER2, promotes a proinflammatory tumor microenvironment. Cancer Immunology Research, 2020, 8, B65-B65.	3.4	3
30	TMIC-09GLIOBLASTOMA STEM CELL-DERIVED EXOSOMES PROMOTE M2 POLARIZATION OF HUMAN MONOCYTES. Neuro-Oncology, 2015, 17, v216.5-v216.	1.2	1
31	Abstract 2180: Genetically engineered chimeric antigen receptor (CAR) monocytes demonstrate targeted anti-tumor activity and differentiate into M1-polarized CAR macrophages. Cancer Research, 2020, 80, 2180-2180.	0.9	1
32	IMPS-41IMMUNE MODULATORY NANOPARTICLE THERAPEUTICS. Neuro-Oncology, 2015, 17, v122.1-v122.	1.2	0
33	IMPS-22FGL2 AS A MULTI-MODALITY REGULATOR OF TUMOR-MEDIATED IMMUNE SUPPRESSION. Neuro-Oncology, 2015, 17, v118.1-v118.	1.2	Ο
34	RTRB-10TYROSINE KINASE RECEPTOR TIE2 REGULATES DNA REPAIR THROUGH THE PROTO-ONCOGENE ABL1 IN BRAIN TUMOR STEM CELLS. Neuro-Oncology, 2015, 17, v197.2-v197.	1.2	0
35	TMIC-04. GLIOBLASTOMA-ASSOCIATED MYELOID CELLS DISPLAY NONPOLARIZED M0 MACROPHAGE PHENOTYPE. Neuro-Oncology, 2016, 18, vi200-vi200.	1.2	Ο
36	TMIC-26. MiR-181a CONTROLS THE OSTEOPONTIN-MEDIATED IMMUNE CIRCUIT IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi261-vi262.	1.2	0

#	Article	IF	CITATIONS
37	Abstract 2136: Nuclear trafficking of Tie2 is associated with radioresistance of gliomas. , 2012, , .		0
38	Abstract B36: Understanding the mechanisms underlying recurrence of malignant gliomas after antiangiogenesis treatment. , 2013, , .		0
39	Abstract 3869: Cell surface vimentin targeted mAb 86C increases sensitivity to temozolomide mediated cell death in glioma stem cells. , 2017, , .		0
40	Abstract 5746: CRISPR9-mediated FGL2-KO in tumor cells impairs tumor progression in brain and triggers antitumor immune memory systematically via NF-ήB dependent Batf3 expression in DCs. , 2018, , .		0
41	Abstract 2907: Exosome secretion is an inheritable property of cancer cells: Single-cell profiling of exosome secretion. , 2019, , .		0
42	Abstract 3242: CT-0508 is an anti-HER2 chimeric antigen receptor (CAR) macrophage with targeted anti-tumor activity that promotes a pro-inflammatory solid tumor microenvironment. , 2020, , .		0
43	Abstract 2193: Small molecule inducible MyD88/CD40 (iMC) in CAR-T cells can repolarize M2 macrophage to an anti-tumor M1 phenotype. , 2020, , .		0